secwatch.observer — SEC 8-K summary
======================================

Issuer:     uniQure N.V. (QURE)
CIK:        0001590560
Form:       8-K
Filed at:   2023-10-05T23:59:59+00:00
Accession:  0001104659-23-107209
Event type: other_material
Sentiment:  negative
Materiality: 0.75
Item codes: 2.05, 5.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

uniQure cuts 28% of workforce, discontinues over half of R&D projects to extend cash runway to Q2 2027
--------------------------------------------------------------------------------

- Workforce reduction of 114 positions (28% of workforce not committed to HEMGENIX) with $180M cost savings over three years.
- Discontinuation of more than half of research projects including AMT-210 for Parkinson's disease.
- Cash runway extended into Q2 2027; $628.6M cash at June 30, 2023 plus $100M milestone from CSL Behring.
- CSO Ricardo Dolmetsch departs; Rich Porter named Chief Business and Scientific Officer effective Oct 5, 2023.
- Clinical focus on AMT-130 (Huntington's), AMT-260 (epilepsy), AMT-162 (SOD1-ALS), and AMT-191 (Fabry).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1590560/000110465923107209/0001104659-23-107209-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1590560/000110465923107209/tm2327835d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-107209

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer